William Blair Upgrades Sarepta Therapeutic (SRPT) to Outperform (Earlier)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
FDA Feedback 'Best Case Scenario' for Sarepta Therapeutic (SRPT), Baird Said; PT Lifted
April 21, 2014 3:41 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $35 to $53 calling the FDA feedback the 'best case scenario.'
Skorney said, "The final FDA minutes reflected several positive outcomes: 1) validation of a historically controlled... More
UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to Buy
April 21, 2014 1:25 PM EDT(Updated - April 21, 2014 1:55 PM EDT)
Canaccord Genuity upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Hold to Buy with a price target of $63.00. Earlier Sarepta announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014. The plan to submit an NDA for eteplirsen by the end of 2014... More
JMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform
April 21, 2014 11:08 AM EDTJMP Securities upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Market Outperform with a price target of $54.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $24.40 yesterday.
... MoreSarepta Therapeutic (SRPT) Target Ratcheted Higher at Needham & Company
April 21, 2014 10:49 AM EDTNeedham & Company analyst Chad Messer, Ph.D reiterated a Buy rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $36 to $52 after a path to accelerated approval of was reached with the FDA.
"Based on a guidance letter recently... More
Sarepta (SRPT) Plans to Submit NDA for Eteplirsen by End of 2014
April 21, 2014 6:57 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Eteplirsen is Sareptas lead exon-skipping drug candidate in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.
The plan to submit an NDA for eteplirsen by the end of 2014 is based on a guidance letter from... More
